Expression of NMDA receptor subunit mRNA after MK-801 treatment in neonatal rats.

Mark McIntosh,'s picture
PubMed URL:
Johnston MV
Author List: 
Wilson MA
Kinsman SL
Johnston MV
Brain Res Dev Brain Res
PubMed ID: 
Although NMDA receptor antagonists are neuroprotective when delivered in conjunction with NMDA, supersensitivity to NMDA-mediated injury follows dizocilpine (MK-801) administration in neonatal rats. An increase in NMDA-sensitive [3H]-glutamate binding accompanies the increase in vulnerability to excitotoxic injury. The present study tests the hypothesis that MK-801 may alter gene expression for the NMDA receptor subunits. Quantitative in situ hybridization histochemistry was used to evaluate the expression of NMDA receptor subunits NR1 and NR2A-D in neonatal rats, 2 to 4 h after treatment with MK-801. Increased mRNA for multiple NMDA receptor subunits was observed in cerebral cortex, striatum and hippocampus. The percent increase in NR2A mRNA was larger than the percent change in NR1, NR2B or NR2D. A small increase in mRNA for the metabotropic glutamate receptor mGluR5 was also observed after MK-801 treatment. These results indicate that gene expression for NMDA receptor subunits in the developing brain is rapidly altered after antagonist exposure. Increased expression of excitatory amino acid receptor subunit mRNA may contribute to the enhanced vulnerability to excitotoxic injury that has been observed after MK-801 treatment.
Published Date: 
August, 1998

Bradley L. Schlaggar, M.D., Ph.D., Named President and CEO of Kennedy Krieger Institute

We’re thrilled to welcome Bradley L. Schlaggar, M.D., Ph.D., to the Kennedy Krieger family as our next President and CEO.

Learn more.

Appointments & Referrals



Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.


Resource Finder


A free resource that provides access to information and support for individuals and families living with developmental disabilities.